AAHA's newly released 2026 Diabetes Management Guidelines for Dogs cover diagnosis, treatment, monitoring, and dietary ...
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the publication of 96-week data from its Phase 3 study of GENGLYCOS™ AAV gene therapy (pariglasgene brecaparvovec-opnr), also known as ...
Type 2 diabetes affects 30% of US adults 65 years or older, many of whom have limited life expectancy, multiple comorbidities ...
LISRAYA represents the first major therapeutic innovation in decades for adults with dermatomyositis (DM), a debilitating ...
LISRAYA represents the first major therapeutic innovation in decades for adults with dermatomyositis (DM), a debilitating ...
Lisraya is the first oral dual TYK2/JAK1 inhibitor indicated for adults with dermatomyositis, demonstrating significant ...
The call comes after an investigation into a 2023 collision between two Canadian National Railway trains near Wainwright, ...
The Food and Drug Administration granted accelerated approval to Zenbexus, or iberdomide, in combination with daratumumab and ...
EDMONTON, Alberta — The Transportation Safety Board of Canada is calling for increased government oversight of assessment of the medical fitness of railway employees as a result of its investigation ...
Orsini, a leader in rare disease pharmacy solutions, announced today that it is a specialty pharmacy partner for Priovant’s LISRAYA™ (brepocitinib), a once-daily oral therapy for the treatment of ...
Advancements in wearable biosensors facilitate continuous health monitoring, delivering personalized insights and improving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results